SCC139 PMC42-LA Human Breast Cancer Cell Line

≥1X10⁶ cells/vial   
Minimum Quantity needs to be mulitiple of
弊社照会 詳細を表示 
    Remaining : Will advise
      Remaining : Will advise
      Contact Customer Service




      Replacement Information


      Key Applications
      Catalogue NumberSCC139
      DescriptionPMC42-LA Human Breast Cancer Cell Line
      OverviewPMC42-LA is a stable epithelial variant of the mesenchyme-like parental PMC42 /PMC42-ET cell line. PMC42-LA congregate into pavement epithelial sheets at high density, in which the cell-cell borders contain E-cadherin and -catenin, albeit 5-10% of cells do express the mesenchymal marker vimentin. When stimulated with epidermal growth factor (EGF), PMC42-LA cells undergo an epithelial-mesenchymal transition in which vimentin expression is upregulated and E-cadherin expression is reduced (5).
      Alternate Names
      • PMC42LA Cell Line
      Background InformationHuman breast carcinoma cell lines are useful models to investigate the pathogenesis of neoplastic transformation and aid in the development of novel therapeutic strategies. Nonetheless, there are few well characterized cell lines derived from human mammary carcinomas and loss of breast-specific marker expression and the emergence of dedifferentiated phenotypes over extended culture often limit their use (1).

      Initiated from a pleural effusion of a metastatic breast cancer patient, the human mesenchymal breast carcinoma cell line PMC42 (also known as PMC42ET), is unique in that these cells remained pleomorphic even after several years of sustained culture (2,3). Typically grown in monolayer, PMC42 continue to give rise to numerous morphologically different cell types of both secretory and myoepithelial characteristics and this retained ability to differentiate in vitro earned their designation as stem cell like (2,3,4).

      1. Engel LW, Young NA (1978) Cancer Res. 38(11 Pt 2):4327-4339.
      2. Whitehead RH et al. (1983) J Natl Cancer Inst 70 (4): 649-661.
      3. Whitehead RH et al. (1983) J Natl Cancer Inst 71(6): 1193-1203.
      4. Ackland ML et al. (2001) Exp Cell Res 263(1): 14–22.
      5. Ackland ML et al. (2003) Lab Invest 83(3): 435–448.
      Product Information
      Quality LevelMQ100
      ApplicationPMC42-LA human breast cancer cell line is a mammary epithelial cell model that can be used to study epithelial to mesenchymal transition.
      Key Applications
      • Cell Culture
      Application NotesThis product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact
      Biological Information
      Cell Line Type
      • Cancer Cells
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assurance• Each vial contains ≥ 1X106 viable cells.
      • Cells are tested by PCR and are negative for HPV-16, HPV-18, Hepatitis A, C, and HIV-1 & 2 viruses.
      • Cells are negative for mycoplasma contamination.
      • Each lot of cells is genotyped by STR analysis to verify the unique identity of the cell line.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStore in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
      Packaging Information
      Material Size≥1X10⁶ cells/vial
      Transport Information
      Supplemental Information